Shattuck Labs Announces Participation in Upcoming November Conferences
Shattuck Labs (NASDAQ: STTK) announced its participation in three investor conferences in November and December 2022. CEO Dr. Taylor Schreiber will present at the Cowen’s 6th Annual IO Next Summit on November 11 and the Evercore ISI HealthCONx Conference on November 29. CFO Andrew Neill will present at the Piper Sandler Healthcare Conference on December 1. The company focuses on developing bi-functional fusion proteins to treat cancer and autoimmune diseases through its proprietary ARC® platform, which targets immune checkpoints and pathways simultaneously.
- Participation in key investor conferences enhances visibility and investor engagement.
- Focus on innovative bi-functional fusion proteins could attract interest from the biotechnology community.
- No new financial metrics or trial updates were provided, leaving investors without critical information.
AUSTIN, TX and DURHAM, NC, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three investor conferences in November 2022.
Presentation Details
Conference: Cowen’s 6th Annual IO Next Summit
Format: Fireside chat with covering analyst Marc Frahm, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: November 11, 2022
Time: 11:40 a.m. ET
Conference: 5th Annual Evercore ISI HealthCONx Conference
Format: Fireside chat with covering analyst Jonathan Miller, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: November 29, 2022
Time: 1:00 p.m. ET
Conference: 34th Annual Piper Sandler Healthcare Conference
Format: Corporate Presentation
Presenter: Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer
Date: December 1, 2022
Time: 11:10 a.m. ET
A live webcast of the fireside chats and presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
What conferences is Shattuck Labs participating in November 2022?
Who will present at the Cowen’s 6th Annual IO Next Summit?
What is the stock symbol for Shattuck Labs?
What is the focus of Shattuck Labs' bi-functional fusion proteins?
